ProCE Banner Activity

Phase III PADA-1 Update: Palbociclib + Switching to Fulvestrant vs Continuing AI Therapy in ER+/HER2- MBC With Rising ESR1 Mutations by ctDNA Analysis

Conference Coverage
Slideset

Updated analysis confirmed PFS benefit of switching to fulvestrant + palbociclib as guided by rising detectable bESR1mut ctDNA during frontline treatment with AI + palbociclib in patients with ER+/HER2- MBC.

Released: June 14, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.